Lung Cancer Research Programs

Institution

Show recipients in

2009

Ignacio Wistuba M.D.

Adenocarcinomas of the lung are pathologically heterogeneous tumors, including the non-invasive bronchioloalveolar (BAC) histology pattern. The BAC component of tumors is considered in most cases...

| More…

2008

Esther P. Black Ph.D.

Approximately 25,000 cases of lung cancer each year are not linked to smoking, the majority occurring in women. These tumors are frequently dependent upon a mutation in the epidermal growth factor...

| More…
Wenrui Duan Ph.D.

75-85% of lung cancers are categorized as non-small cell cancers. p53 mutations are reported in 50-60% of non-small cell lung cancers and in up to 90% of small cell tumors, thus p53 represents a...

| More…
Sizhi Paul Gao Ph.D.

Approximately 10% of lung cancers occur in never-smokers and typically harbor a mutant form of the epidermal growth factor receptor (EGFR). Although most of these patients initially respond to...

| More…
Robert I. Glazer Ph.D.

Bronchioalveolar carcinoma (BAC) is a subtype of lung cancer that accounts for approximately 20% of lung cancers, including those with a mixed histology. BAC occurs more frequently among...

| More…
Randolph Hastings M.D., Ph.D.

Bronchioalveolar carcinoma (BAC) is a form of lung cancer characterized by non-invasive growth. The tumors expand within the confines of the existing air space in the lung without invading the...

| More…
Faye Johnson M.D., Ph.D.

Better therapies are needed for patients with non-small cell lung cancer (NSCLC). One promising target for therapy is a protein called EphA2 that is expressed on the surface of NSCLC tumor cells...

| More…
William Y. Kim M.D.

A better understanding of the molecular biology and genetics of these tumors and, in particular, identification of pathways that are amenable to targeting with current therapies are required to...

| More…
Rachel M.A. Linger Ph.D.

Dr. Linger’s research is focused on the role of a protein called Axl receptor tyrosine kinase in lung cancer. The presence of Axl makes lung cancer cells more invasive and increases the chance...

| More…
Philip C. Mack Ph.D.

Although cancer biomarkers predictive of a lung cancer patient’s response to certain therapies have been recognized, routine patient screening has not been put into practice. For example,...

| More…